Evidence map›Paper›PMID 38234720›Full record

ArticlebioRxiv : the preprint server for biology2023

Identification of a Musashi2 translocation as a novel oncogene in myeloid leukemia.

Kyle Spinler, Michael Hamilton, Jeevisha Bajaj, Yutaka Shima, Emily Diaz, Marcie Kritzik, Tannishtha Reya

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kyle SpinlerDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Michael HamiltonDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Jeevisha BajajDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Yutaka ShimaDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Emily DiazDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Marcie KritzikDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.
Tannishtha ReyaDepartments of Pharmacology and Medicine, University of California San Diego School of Medicine La Jolla, CA.ORCID 0000-0002-5956-8536
University of California San Diego · USColumbia University Irving Medical Center · US

Funding

GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
Contemporary Approaches to Cancer Cell Signaling and CommunicationT32CA009523 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DONOGHUE, DANIEL J, YANG, JING · 1985 to 2025
$12.1M
Molecular strategies for early detection and targeting of cancerR35CA197699 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tannishtha Reya · 2015 to 2026
$11.2M
U of Calif, San Diego Neuroscience Microscopy ImagingP30NS047101 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLEESON, JOSEPH G, ZHENG, BINHAI · 2003 to 2022
$9.0M
Blood Cells in Hemostasis and ThrombosisT32HL086344 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GINSBERG, MARK HOWARD · 2008 to 2023
$4.4M
NCI NIH HHS R35 CA197699NCI NIH HHS T32 CA009523NHLBI NIH HHS T32 HL086344NIGMS NIH HHS T32 GM007752NINDS NIH HHS P30 NS047101
6 · The paper itself

Abstract

Myeloid leukemias, diseases marked by aggressiveness and poor outcomes, are frequently triggered by oncogenic translocations. In the case of chronic myelogenous leukemia (CML) the BCR-ABL fusion initiates chronic phase disease with second hits allowing progression to blast crisis. Although Gleevec has been transformative for CML, blast crisis CML remains relatively drug resistant. Here we show that MSI2-HOXA9, a translocation with an unknown role in cancer, can serve as a second hit in driving bcCML. Compared to BCR-ABL, BCR-ABL/MSI2-HOXA9 led to a more aggressive disease

Identifiers

PMID38234720
PMCPMC10793452
OpenAlexW4390430001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.